danalcock, Author at European Medical Journal - Page 14 of 15

Turning patient insights into action

Pharma endeavours to drive positive action from patient insights. Read to find out how they could improve their methodologies and outcomes.

Mitigating the rare disease RWD deficit

RWD for rare diseases is scarce, but pharma can work to leverage existing processes and build trust to enhance the scope of available data.

Is the generics and biosimilars sector at risk of collapse?

Generics and biosimilars are crucial to healthcare worldwide, but there are challenges in getting these medicine to patients.

Confronting health inequities for transgender patients

The challenges faced by the transgender community are vast, but pharma has the power to drive better health equity. Read more.

The politics of vaccine replication and access

With Moderna pledging not to enforce its COVID-19 vaccine patent in 92 LMICs, a hub in South Africa is pushing ahead with replication. Read for more details.

Revealing the true value of medical affairs

Why is the purpose and value of medical affairs sometimes poorly understood by the wider pharma organisation, and what can be done?

The changing rhythm of digital therapeutics

Digital therapeutics are making their way onto the main stage, and pharma should be taking note. What lies ahead for potential partnerships?

The uphill recruitment battle

Recruitment for pharma is not an easy task, especially when the goal is to appeal to the younger generation. Read the article and find out more.

Resilience After Rejection

Rejection is always painful, but it is particularly agonising to have a drug rejected at the point of regulatory approval. After spending months researching, preparing, manufacturing and quality checking a drug, only to be sent back to the drawing board, how can companies get back into their creationary swing straight away?

The rare disease disparity

Some thoughts about how the Rare Disease Act impacted pharma and if it needs further updating after almost 20 years.